Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Tempest Therapeutics, Inc. TPST

14 fiscal years on record · USD · FY2025 reported · SEC filings only
$-26.3M
$-26.8M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

We are a clinical-stage biotechnology company advancing a diversified portfolio of cell therapy and small molecule product candidates. Our portfolio also includes two clinical-stage small molecule product candidates with the potential to treat certain cancer indications. One of our small-molecule product candidates, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma (“HCC”). Our mission is to develop therapeutic products with the potential to address high unmet medical needs by identifying promising clinical-stage candidates and advancing their development to create products that will improve patients’ lives.

Written from the business description in Tempest Therapeutics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 30 March 2026. Every sentence was checked against that document before publication.

Growth

·
Revenue, FY2025 · full 14-year series below
Revenue $M Net income $M
FY2017 · Revenue 0.3 · Net income -84.6
-30M-60M
201220152018202120242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2017 · Operating -28585.1%
-10000%-20000%
201220182025
ROE
FY2025 · ROE -203.6%
-100%-200%
201220182025
Three returns, three denominators.

Each USD of equity lost 204 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -26.8
-25.0M-50.0M
201220182025

Total assetsUSD 16.9M
EquityUSD 6.7M
CashUSD 7.7M
Gross debtUSD 0.00
Net debtUSD -7.7M
Current ratio2.50×

The company holds more cash than debt.

The 14-year record

14 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
TPST, 14-year financial record
Metric 20252024202320222021202020192018201720162015201420132012
Revenue $B◌◌◌◌◌◌◌◌0.00.00.00.00.0◌
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.1−0.1−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.1−0.1−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.0◌◌0.00.00.00.00.00.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.1−0.1−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.1−0.0−0.0−0.0
EPS, diluted $−6.33−19.50−1.91−3.09−7.47−41.03−3.25−17.58−321.81−2.56−2.70−2.19−1.80−2.33
Dividend / sh $◌◌◌◌◌0.000.000.00◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————————
ROE %−203.6−182.3−131.4−131.7—————−70.0−80.4−102.1−80.2—
Shares out B0.000.040.020.010.010.020.020.000.000.040.030.020.020.01

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 59 reconciliationsAUDITED

Reconciled in 14 of the 14 fiscal years we could check. Eight checks were skipped: the balance sheet is not tagged before 2011. Six checks were skipped: revenue is not tagged before 2013. Five checks were skipped: EPS is not tagged before 2012.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2011

Share this section

Download image